Form 4 Filing for Jan Pinkas

Jan Pinkas, Chief Scientific Officer of CRESCENT BIOPHARMA, INC., reported the sale of 658 ordinary shares on September 16, 2026. The shares were sold at a weighted average price of $17.90 per share, with individual sales ranging from $17.10 to $19.17. These sales were conducted to cover tax withholding obligations in connection with the settlement of restricted stock units granted on December 15, 2025. The transactions were executed under a Rule 10b5-1 instruction adopted on February 26, 2026, specifically to address tax liabilities upon the vesting of restricted stock units. Following these transactions, Pinkas owns 21,581 shares.